Comment on: “Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag”

Authors’ Reply to Srinivas: “Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag”

“…Srinivas indicated that the data described in our paper suggested absorption limitation of selexipag at a threshold of 800 lg [1]. However, the single-dose data for both selexipag and ACT-333679 showed a dose-proportional increase in both exposure variables across the dose range tested, from 100 to 800 lg [2].…”

“…We thank Dr. Srinivas for his interest in our study and for the opportunity to respond to the letter [1]. While we agree with several points, there are others we disagree with.…”

“…

We thank Dr. Srinivas for his interest in our study and for the opportunity to respond to the letter [1]. While we agree with several points, there are others we disagree with.

Taking into consideration the much higher potency at the prostacyclin receptor (IP) and the pharmacokinetic characteristics, it is acknowledged that ACT-333679 is the major contributor to the overall efficacy as well as to potential safety relevant effects.

…”